Skip to main content
main-content
Erschienen in: InFo Hämatologie + Onkologie 1-2/2021

22.02.2021 | Tyrosinkinaseinhibitoren | Schwerpunkt

Schwerpunkt Tyrosinkinaseinhibitor-Wechselwirkungen

Arzneimittelinteraktionen zwischen oralen TKI und pflanzlichen Präparaten

verfasst von: Prof. Dr. rer. nat. Christoph A. Ritter

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 1-2/2021

Einloggen, um Zugang zu erhalten

Auszug

Pflanzliche Präparate bergen ein spezielles Risiko für Wechselwirkungen mit oralen Tyrosinkinaseinhibitoren. Woran das liegt und wie sich diese Wechselwirkungsrisiken in der Praxis abschätzen und bewerten lassen, ist Gegenstand dieses Übersichtsartikels.
Literatur
1.
Zurück zum Zitat Horneber M et al. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther. 2012;11(3):187-203 Horneber M et al. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther. 2012;11(3):187-203
2.
Zurück zum Zitat König J et al. Use of Complementary and Alternative Medicine in Cancer Patients: A Prospective Questionnaire-Based Study in an Oncological Outpatient Clinic. Oncol Res Treat. 2016;39(5):260-5 König J et al. Use of Complementary and Alternative Medicine in Cancer Patients: A Prospective Questionnaire-Based Study in an Oncological Outpatient Clinic. Oncol Res Treat. 2016;39(5):260-5
3.
Zurück zum Zitat Hierl M et al. Complementary and Alternative Medicine: A Clinical Study in 1,016 Hematology/Oncology Patients. Oncology. 2017;93(3):157-63 Hierl M et al. Complementary and Alternative Medicine: A Clinical Study in 1,016 Hematology/Oncology Patients. Oncology. 2017;93(3):157-63
4.
Zurück zum Zitat Wode K et al. Cancer patients' use of complementary and alternative medicine in Sweden: a cross-sectional study. BMC Complement Altern Med. 2019;19(1):62 Wode K et al. Cancer patients' use of complementary and alternative medicine in Sweden: a cross-sectional study. BMC Complement Altern Med. 2019;19(1):62
5.
Zurück zum Zitat Markowitz JS et al. Limitations of in vitro assessments of the drug interaction potential of botanical supplements. Planta Med. 2012;78(13):1421-7 Markowitz JS et al. Limitations of in vitro assessments of the drug interaction potential of botanical supplements. Planta Med. 2012;78(13):1421-7
6.
Zurück zum Zitat Goey AKL et al. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treat Rev. 2013;39(7):773-83 Goey AKL et al. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treat Rev. 2013;39(7):773-83
7.
Zurück zum Zitat www.onkopedia.com/de/onkopedia/guidelines/arzneimittelinteraktionen abgerufen am 20. Januar 2021 www.onkopedia.com/de/onkopedia/guidelines/arzneimittelinteraktionen abgerufen am 20. Januar 2021
8.
Zurück zum Zitat Yap KY et al. Utilizing mobile networks for the detection of clinically relevant interactions between chemotherapy regimens and complementary and alternative medicines. J Altern Complement Med. 2012;18(2):165-74 Yap KY et al. Utilizing mobile networks for the detection of clinically relevant interactions between chemotherapy regimens and complementary and alternative medicines. J Altern Complement Med. 2012;18(2):165-74
9.
Zurück zum Zitat www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf abgerufen am 20. Januar 2021 www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf abgerufen am 20. Januar 2021
10.
Zurück zum Zitat Lipp HP. Arzneimittelinteraktionen mit Nahrung und Magen-pH. InFo Hämatologie + Onkologie. 2020;24(1-2):10-7 Lipp HP. Arzneimittelinteraktionen mit Nahrung und Magen-pH. InFo Hämatologie + Onkologie. 2020;24(1-2):10-7
11.
Zurück zum Zitat Sprouse AA et al. Pharmacokinetic Interactions between Drugs and Botanical Dietary Supplements. Drug Metab Dispos. 2016;44(2):162-71 Sprouse AA et al. Pharmacokinetic Interactions between Drugs and Botanical Dietary Supplements. Drug Metab Dispos. 2016;44(2):162-71
12.
Zurück zum Zitat Güthlin C et al. A Germany-Wide Collaborative Research Project to Identify Needs, Provide Information, Foster Communication and Support Decision-Making about Complementary and Alternative Medicine in Oncology. Complement Med Res. 2020;27(2):105-111 Güthlin C et al. A Germany-Wide Collaborative Research Project to Identify Needs, Provide Information, Foster Communication and Support Decision-Making about Complementary and Alternative Medicine in Oncology. Complement Med Res. 2020;27(2):105-111
13.
Zurück zum Zitat Ziemann J et al. Herb-drug interactions: a novel algorithm-assisted information system for pharmacokinetic drug interactions with herbal supplements in cancer treatment. Eur J Clin Pharmacol. 2019;75(9):1237-48 Ziemann J et al. Herb-drug interactions: a novel algorithm-assisted information system for pharmacokinetic drug interactions with herbal supplements in cancer treatment. Eur J Clin Pharmacol. 2019;75(9):1237-48
14.
Zurück zum Zitat Hussaarts KGAM et al. Clinically relevant drug interactions with multikinase inhibitors: a review. Ther Adv Med Oncol. 2019;11:1758835918818347 Hussaarts KGAM et al. Clinically relevant drug interactions with multikinase inhibitors: a review. Ther Adv Med Oncol. 2019;11:1758835918818347
15.
Zurück zum Zitat Frank A, Unger M. Analysis of frankincense from various Boswellia species with inhibitory activity on human drug metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated on-line extraction. J Chromatogr A. 2006;1112(1-2):255-62 Frank A, Unger M. Analysis of frankincense from various Boswellia species with inhibitory activity on human drug metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated on-line extraction. J Chromatogr A. 2006;1112(1-2):255-62
16.
Zurück zum Zitat Gurley BJ et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther. 2002;72(3):276-87 Gurley BJ et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther. 2002;72(3):276-87
17.
Zurück zum Zitat Gurley BJ et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging. 2005;22(6):525-39 Gurley BJ et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging. 2005;22(6):525-39
18.
Zurück zum Zitat Kim DS et al. Effect of Red Ginseng on cytochrome P450 and P-glycoprotein activities in healthy volunteers. J Ginseng Res. 2016;40(4):375-81 Kim DS et al. Effect of Red Ginseng on cytochrome P450 and P-glycoprotein activities in healthy volunteers. J Ginseng Res. 2016;40(4):375-81
19.
Zurück zum Zitat Seong SJ et al. A Comprehensive In Vivo and In Vitro Assessment of the Drug Interaction Potential of Red Ginseng. Clin Ther. 2018;40(8):1322-37 Seong SJ et al. A Comprehensive In Vivo and In Vitro Assessment of the Drug Interaction Potential of Red Ginseng. Clin Ther. 2018;40(8):1322-37
20.
Zurück zum Zitat Malati CY et al. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. J Clin Pharmacol. 2012;52(6):932-9 Malati CY et al. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. J Clin Pharmacol. 2012;52(6):932-9
21.
Zurück zum Zitat Gurley BJ et al. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos. 2006;34(1):69-74 Gurley BJ et al. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos. 2006;34(1):69-74
22.
Zurück zum Zitat Han Y et al. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers. Xenobiotica. 2009;39(9):694-9 Han Y et al. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers. Xenobiotica. 2009;39(9):694-9
23.
Zurück zum Zitat Gurley BJ et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther. 2004;76(5):428-40 Gurley BJ et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther. 2004;76(5):428-40
24.
Zurück zum Zitat Gorski JC et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther. 2004;75(1):89-100 Gorski JC et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther. 2004;75(1):89-100
25.
Zurück zum Zitat Chrubasik-Hausmann S et al. Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content. J Pharm Pharmacol. 2019;71(1):129-38 Chrubasik-Hausmann S et al. Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content. J Pharm Pharmacol. 2019;71(1):129-38
26.
Zurück zum Zitat Gurley BJ et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005;77(5):415-26 Gurley BJ et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005;77(5):415-26
27.
Zurück zum Zitat Donovan JL et al. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos. 2004;32(12):1333-6 Donovan JL et al. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos. 2004;32(12):1333-6
28.
Zurück zum Zitat Doroshyenko O et al. Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers. Drug Metab Dispos. 2013;41(5):987-93 Doroshyenko O et al. Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers. Drug Metab Dispos. 2013;41(5):987-93
29.
Zurück zum Zitat Farkas D et al. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. J Clin Pharmacol. 2007;47(3):286-94 Farkas D et al. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. J Clin Pharmacol. 2007;47(3):286-94
30.
Zurück zum Zitat Misaka S et al. Effect of 2 weeks' consumption of pomegranate juice on the pharmacokinetics of a single dose of midazolam: an open-label, randomized, single-center, 2-period crossover study in healthy Japanese volunteers. Clin Ther. 2011;33(2):246-52 Misaka S et al. Effect of 2 weeks' consumption of pomegranate juice on the pharmacokinetics of a single dose of midazolam: an open-label, randomized, single-center, 2-period crossover study in healthy Japanese volunteers. Clin Ther. 2011;33(2):246-52
31.
Zurück zum Zitat Abdlekawy KS et al. Effects of Grapefruit and Pomegranate Juices on the Pharmacokinetic Properties of Dapoxetine and Midazolam in Healthy Subjects. Eur J Drug Metab Pharmacokinet. 2017;42(3):397-405 Abdlekawy KS et al. Effects of Grapefruit and Pomegranate Juices on the Pharmacokinetic Properties of Dapoxetine and Midazolam in Healthy Subjects. Eur J Drug Metab Pharmacokinet. 2017;42(3):397-405
32.
Zurück zum Zitat Donovan JL et al. Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. Drug Metab Dispos. 2004;32(9):906-8 Donovan JL et al. Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. Drug Metab Dispos. 2004;32(9):906-8
33.
Zurück zum Zitat Chow HH et al. Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev. 2006;15(12):2473-6 Chow HH et al. Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev. 2006;15(12):2473-6
34.
Zurück zum Zitat Thu OK et al. Effect of commercial Rhodiola rosea on CYP enzyme activity in humans. Eur J Clin Pharmacol. 2016;72(3):295-300 Thu OK et al. Effect of commercial Rhodiola rosea on CYP enzyme activity in humans. Eur J Clin Pharmacol. 2016;72(3):295-300
35.
Zurück zum Zitat Gurley B et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol. 2006;46(2):201-13 Gurley B et al. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol. 2006;46(2):201-13
Metadaten
Titel
Schwerpunkt Tyrosinkinaseinhibitor-Wechselwirkungen
Arzneimittelinteraktionen zwischen oralen TKI und pflanzlichen Präparaten
verfasst von
Prof. Dr. rer. nat. Christoph A. Ritter
Publikationsdatum
22.02.2021
Verlag
Springer Medizin
Erschienen in
InFo Hämatologie + Onkologie / Ausgabe 1-2/2021
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI
https://doi.org/10.1007/s15004-021-8543-8

Weitere Artikel der Ausgabe 1-2/2021

InFo Hämatologie + Onkologie 1-2/2021 Zur Ausgabe

Passend zum Thema

ANZEIGE
ALK-TKI für die Erstlinie

Erweiterung der Therapieoptionen für fortgeschrittenes ALK+ NSCLC

ALK-TKI haben sich in der Behandlung des fortgeschrittenen ALK+ NSCLC bewährt. Ab sofort steht Patient:innen ein weiterer Vertreter für die Erstlinientherapie zur Verfügung. Studiendaten belegen eine deutliche Risikoreduktion für Progress und Tod sowie eine starke intrakranielle Wirksamkeit.